BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
Ranibizumab: trial readouts and FDA decisions
3 upcoming industry Phase 2/3 readout(s) in the next 90 days, 0 upcoming FDA event(s), 3 readout(s) in the last 180 days and 0 FDA event(s) in the last 12 months. Sponsors: AbbVie, EyeBiotech Ltd., Hoffmann-La Roche. Drug names come from ClinicalTrials.gov intervention names and FDA records, lightly normalised; one drug can appear under several names (code, generic, brand).
Upcoming trial readouts
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-12 est. | P2/P3 | AbbVie ABBV | NCT04704921 Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD | AMD; nAMD; Wet Age-related Macular Degeneration; wAMD; Wet AMD; CNV; Neovascular AMD; Neovascular Ag | active not recruiting | 671 |
| 2027-01-11 est. | P2/P3 | EyeBiotech Ltd. | NCT06957080 A Study of 2 Doses of Remigromig (EYE103) Compared With Ranibizumab (0.5 mg) in Participants With DME | Diabetic Macular Edema (DME) | active not recruiting | 1054 |
| 2027-02-04 est. | P3 | Hoffmann-La Roche | NCT04657289 A Study of the Efficacy, Safety, and Pharmacokinetics of a 36-Week Refill Regimen for the Port Delivery System With Ranibizumab in Patients With Neovascular Age | Neovascular Age-related Macular Degeneration (nAMD) | active not recruiting | 451 |
Readouts, last 180 days
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-10-13 | P2 | AbbVie ABBV | NCT04514653 RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD) | Neovascular Age-Related Macular Degeneration (nAMD) | active not recruiting | 146 |
| 2026-08-25 | P1/P2 | Hoffmann-La Roche | NCT04567303 Study of Zifibancimig in Participants With Neovascular Age-related Macular Degeneration | Macular Degeneration | completed | 177 |
| 2026-07-14 | P2/P3 | EyeBiotech Ltd. | NCT06571045 A Study to Evaluate the Efficacy and Safety of 2 Doses of Remigromig (EYE103) Compared With Ranibizumab (0.5 mg) in Participants With DME | Diabetic Macular Edema (DME) | active not recruiting | 984 |
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.